Prostatitis is an umbrella term for several quite different conditions, and the name causes considerable confusion because most cases do not involve infection or even significant inflammation of the prostate. Acute bacterial prostatitis is a genuine infection: sudden fever, chills, severe pelvic and perineal pain and difficulty passing urine, requiring prompt antibiotics. Chronic bacterial prostatitis, a small minority of cases, causes recurrent urinary infections with the same organism from a persistent prostatic focus. But the great majority of men diagnosed with prostatitis have chronic prostatitis/chronic pelvic pain syndrome — persistent pelvic, perineal, testicular or ejaculatory pain with urinary symptoms, in which no infection can be found and the mechanism involves pelvic floor muscle dysfunction, nerve sensitisation and pain processing rather than the prostate itself.

Why did the antibiotics not work?

Because in the great majority of cases there was nothing for them to treat. Randomised trials comparing antibiotics with placebo in men with chronic pelvic pain syndrome and negative cultures have shown no benefit. What happens instead is that the first course coincides with a natural fluctuation in symptoms, this is interpreted as partial response, and further and longer courses follow — often for years. The harms accumulate: side effects, disruption of the gut microbiome, antibiotic resistance, and the risks specific to fluoroquinolones, which include tendon rupture, nerve damage that may be permanent, and aortic complications. The most significant harm, though, is delay: every month spent on ineffective antibiotics is a month not spent on pelvic floor physiotherapy, neuromodulators and pain management, while the condition becomes more entrenched.

What actually helps chronic pelvic pain syndrome?

Treatment directed at the specific problems each individual man has, rather than a single drug tried in sequence. The UPOINT approach assesses six domains — urinary symptoms, psychosocial factors, prostate-specific symptoms, genuine infection, neurological or systemic pain features, and pelvic muscle tenderness — and treats each one that is present. The intervention with the most consistent evidence is specialist pelvic floor physiotherapy: many men have tight, tender pelvic floor muscles with trigger points, and manual release with relaxation training helps substantially. Importantly, standard pelvic floor strengthening exercises usually make things worse, because the muscles are already over-contracted. Other effective components: low-dose neuromodulators such as amitriptyline, gabapentinoids or duloxetine; cognitive behavioural therapy, which addresses the catastrophising that genuinely amplifies pain; and alpha-blockers where urinary symptoms dominate.

Does prostatitis affect the PSA test or cause cancer?

Prostatitis does not cause prostate cancer, but it does affect the PSA test, and this causes real problems in both directions. Inflammation of the prostate can raise PSA substantially — sometimes to levels that appear alarming — so PSA should not be checked during an acute episode or a symptomatic flare. If it has been, it should be repeated after at least six to eight weeks of settled symptoms before any decision about MRI or biopsy, since many men undergo unnecessary biopsies for what turns out to be inflammation. The opposite error is equally important: prostatitis should not become the automatic explanation for every raised PSA. If PSA remains elevated after treatment, if it is rising, or if the prostate feels abnormal on examination, proper evaluation with MRI and biopsy is needed regardless of a prostatitis label.

When is prostatitis an emergency?

Acute bacterial prostatitis can progress to sepsis and needs urgent assessment when there is high fever with shaking chills, severe pain, feeling very unwell, or inability to pass urine. Two practical points matter in this situation. First, if the bladder cannot be emptied, a catheter should be placed through the abdominal wall (suprapubic) rather than through the urethra, because passing a catheter through an acutely infected prostate risks worsening the infection and causing an abscess. Second, if fever and pain do not improve within two to three days of appropriate antibiotics, a prostatic abscess should be suspected and imaging arranged, since abscesses need drainage rather than more antibiotics. Vigorous prostate massage, sometimes used diagnostically in chronic cases, must be avoided in acute infection because it can push bacteria into the bloodstream.

How does GMJ News cover prostatitis?

GMJ News covers the NIH classification and the misleading nature of the term, the evidence against antibiotics in culture-negative CP/CPPS and the resulting harms, fluoroquinolone safety restrictions, UPOINT phenotyping and multimodal therapy, pelvic floor physiotherapy and why strengthening exercises are counterproductive, central sensitisation and overlap with IBS, fibromyalgia and bladder pain syndrome, the NIH-CPSI outcome measure, acute bacterial prostatitis management including suprapubic catheterisation and abscess recognition, and the effect of prostatitis on PSA interpretation in both directions. Relevant to PHIG's men's health, chronic pain and antimicrobial stewardship programmes.

Home › Topics › Prostatitis and Chronic Pelvic Pain

Prostatitis and Chronic Pelvic Pain

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Prostatitis syndromes account for a substantial share of urology consultations in men under fifty, but the term is deeply misleading: fewer than 10% of cases involve bacterial infection at all, and the great majority are chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS, NIH category III) — a chronic pain condition involving pelvic floor muscle dysfunction, central sensitisation, neuropathic mechanisms and psychosocial factors rather than prostatic infection (WHO). The consequence of the misnomer is measurable harm: men are given repeated prolonged courses of antibiotics that trials show to be no better than placebo in antibiotic-naive-negative disease, while the interventions with genuine evidence — pelvic floor physiotherapy, neuromodulators, and phenotype-directed multimodal therapy using the UPOINT system — are delayed for years. Acute bacterial prostatitis (category I) is an entirely different entity: a genuine and potentially septic infection requiring prompt antibiotics and, where retention occurs, suprapubic rather than urethral catheterisation.

Key messages

Fewer than 10% of prostatitis cases involve bacterial infection

The name is the problem. Under the NIH classification, the great majority of cases are category III — chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) — in which no uropathogen is identified and the mechanism is not prostatic infection at all. Categories: I acute bacterial prostatitis; II chronic bacterial prostatitis (recurrent UTI with the same organism, around 5-10%); III CP/CPPS (IIIa inflammatory, IIIb non-inflammatory) — the overwhelming majority; IV asymptomatic inflammatory prostatitis, found incidentally on biopsy or semen analysis and requiring no treatment.

Repeated antibiotic courses cause measurable harm

Randomised trials of antibiotics in antibiotic-naive-negative CP/CPPS show no benefit over placebo, yet men routinely receive multiple prolonged courses over years. The harms are real and cumulative: adverse effects, Clostridioides difficile risk, antimicrobial resistance, cost, and — most importantly — years of delay before effective treatment is started, during which central sensitisation and disability become entrenched. Fluoroquinolones, still commonly used, carry additional risks of tendinopathy, aortic aneurysm and dissection, and disabling neuropsychiatric effects, and regulatory bodies have restricted their use for exactly this kind of indication.

UPOINT phenotyping directs multimodal therapy

CP/CPPS is heterogeneous, which is why single-modality treatment fails. The UPOINT system phenotypes each patient across six domains and treats each identified domain: Urinary (alpha-blockers, antimuscarinics); Psychosocial (CBT, catastrophising and depression management); Organ-specific (prostate-directed therapy, alpha-blockers, 5-ARIs); Infection (antibiotics ONLY if genuinely documented); Neurologic/systemic (neuromodulators — gabapentinoids, amitriptyline, duloxetine; management of coexisting IBS, fibromyalgia, chronic fatigue); Tenderness of skeletal muscle (pelvic floor physiotherapy, trigger point release). Multimodal, phenotype-directed treatment substantially outperforms sequential monotherapy.

Pelvic floor physiotherapy has the strongest evidence of any intervention

A large proportion of men with CP/CPPS have pelvic floor muscle dysfunction — hypertonicity, myofascial trigger points and impaired relaxation — identifiable on digital examination as reproducible tenderness in the levator ani and obturator internus. Specialist pelvic floor physiotherapy with myofascial trigger point release, paradoxical relaxation training and, where appropriate, internal manual therapy, has the most consistent evidence base for symptom improvement. Kegel-style strengthening exercises are inappropriate and typically worsen symptoms, since the problem is excessive tone rather than weakness — a distinction frequently missed when men are given generic pelvic floor advice.

Acute bacterial prostatitis is a different disease — and avoid urethral catheterisation

Category I acute bacterial prostatitis presents with fever, rigors, perineal and pelvic pain, obstructive voiding symptoms and an exquisitely tender prostate, and can progress rapidly to sepsis. Treatment: prompt antibiotics guided by local resistance patterns, with a prolonged course (typically 2-4 weeks) to achieve prostatic penetration and prevent progression to chronic bacterial prostatitis or abscess. Two practical points: vigorous prostatic massage is contraindicated in acute prostatitis because of bacteraemia risk; and if urinary retention develops, SUPRAPUBIC catheterisation is preferred over urethral, which risks worsening infection and abscess formation. Failure to improve within 48-72 hours should prompt imaging for prostatic abscess.

Prostatitis raises PSA — do not misinterpret it

Prostatic inflammation, whether infective or not, can raise serum PSA substantially and produce an alarming result that is nonetheless benign. PSA should not be measured during acute prostatitis or symptomatic flares; if it has been, it should be repeated after at least 6-8 weeks of symptom resolution before any decision about biopsy. Conversely, prostatitis must not become a reflex explanation for every raised PSA — persistent elevation after treatment, an abnormal digital rectal examination, or a rising trend requires proper evaluation with MRI and biopsy. Both errors occur commonly: unnecessary biopsy for inflammation, and missed cancer attributed to prostatitis.

Key statistics

<10%

of prostatitis cases involve identifiable bacterial infection — the name misleads

NIH/EAU

Category III

CP/CPPS accounts for the great majority of cases; category IV requires no treatment

NIH classification

No benefit

antibiotics show no advantage over placebo in antibiotic-naive-negative CP/CPPS in RCTs

Ann Intern Med/EAU

UPOINT

phenotype-directed multimodal therapy outperforms sequential monotherapy

EAU/AUA

Suprapubic

catheterisation preferred over urethral in acute bacterial prostatitis with retention

EAU

PSA raised

by prostatitis — repeat after 6-8 weeks of symptom resolution before considering biopsy

EAU/AUA

CP/CPPS — evidence for common interventions

Source: EAU/AUA/Cochrane. Physiotherapy and multimodal phenotype-directed care lead; antibiotics have no role in culture-negative disease.

Glossary of key terms

NIH prostatitis classification
UrologyCategory I — acute bacterial prostatitis: acute febrile illness with positive urine culture. Category II — chronic bacterial prostatitis: recurrent urinary tract infections with the same organism, arising from a persistent prostatic focus; around 5-10% of cases; genuinely responds to prolonged antibiotics. Category III — chronic prostatitis/chronic pelvic pain syndrome: pelvic pain for at least three of the previous six months with no demonstrable infection; subdivided into IIIa (inflammatory — leucocytes in expressed prostatic secretions, post-massage urine or semen) and IIIb (non-inflammatory); the distinction has little therapeutic consequence. Category IV — asymptomatic inflammatory prostatitis: inflammation found incidentally on biopsy performed for other reasons or on semen analysis, with no symptoms; requires no treatment and should not be reported in a way that generates anxiety or unnecessary therapy.

NIH-CPSI symptom index
Outcome measurementThe NIH Chronic Prostatitis Symptom Index is the standard instrument, with nine items across three domains: pain (location, frequency, severity — 0-21), urinary symptoms (0-10), and quality of life impact (0-12), giving a total of 0-43. It is used to establish baseline severity, guide treatment intensity and, crucially, measure response over time — a reduction of around 6 points is generally regarded as clinically meaningful. Its value in a condition dominated by subjective symptoms and long treatment courses is considerable: without objective serial measurement, both clinician and patient lose track of whether an intervention is working, which contributes to the pattern of indefinite ineffective treatment.

Central sensitisation in chronic pelvic pain
Pain medicineCP/CPPS shares mechanisms with other chronic overlapping pain conditions, and many men have more than one: irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, chronic tension headache and interstitial cystitis/bladder pain syndrome. The common feature is central sensitisation — amplified central processing of nociceptive input, with lowered pain thresholds, spread of pain beyond the original site, and hyperalgesia. Recognising this reframes management entirely: it explains why organ-directed treatments fail, why neuromodulators and psychological therapies work, and why the search for a hidden prostatic infection is futile. It also explains why catastrophising and depression are not merely consequences of the pain but active drivers of its severity and persistence, and therefore legitimate treatment targets.

Interstitial cystitis / bladder pain syndrome
UrologyThe closest analogue in women and an important differential in both sexes: chronic pelvic pain perceived to be related to the bladder, with urinary frequency and urgency, in the absence of infection or other identifiable cause. Shares the central sensitisation mechanism, the overlap with other chronic pain conditions, and the same clinical trap of repeated futile antibiotic courses for culture-negative symptoms. Management principles mirror CP/CPPS: education and reassurance, dietary trigger identification, pelvic floor physiotherapy where hypertonicity is present, neuromodulators, and psychological therapy — with bladder-directed interventions (intravesical instillations, hydrodistension) and, for the specific Hunner lesion phenotype, targeted endoscopic treatment. Recognising the shared framework prevents both conditions from being managed as chronic infection.

Fluoroquinolone safety restrictions
PharmacovigilanceFluoroquinolones have long been the default in prostatitis because of good prostatic penetration, but regulatory agencies including the FDA and EMA have restricted their use following recognition of serious, sometimes irreversible adverse effects: tendinitis and tendon rupture (particularly Achilles, with risk increased by age, corticosteroids and renal impairment); peripheral neuropathy, which may be permanent; central nervous system effects including confusion, agitation and psychosis; aortic aneurysm and dissection; and QT prolongation. Guidance is explicit that they should not be used for conditions where they offer no clear advantage or where the condition is self-limiting or not infective. Prescribing prolonged repeated fluoroquinolone courses for culture-negative CP/CPPS is precisely the pattern these restrictions were designed to prevent.

Prostatic abscess
Emergency urologyA complication of acute bacterial prostatitis to consider whenever a patient fails to improve within 48-72 hours of appropriate antibiotics, or has persistent swinging fever, severe perineal pain, or retention. Risk factors: diabetes, immunosuppression, HIV, urethral instrumentation and indwelling catheters. Diagnosis: transrectal ultrasound or CT/MRI of the pelvis. Management: prolonged intravenous antibiotics with drainage of collections — transrectal or transperineal aspiration, or transurethral deroofing for larger abscesses. In immunocompromised patients and in high-prevalence regions, consider unusual organisms including Burkholderia pseudomallei (melioidosis, which has a particular predilection for prostatic abscess in endemic areas) and tuberculosis.

Latest GMJ coverage

Articles will appear here as the archive grows.

Prostatitis and Chronic Pelvic Pain

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company